associated with these therapies could be caused by regression of capillaries around thyroid follicles. Clinical or laboratory evidence of hypothyroidism has been found in a significant proportion of patients on sunitinib and may contribute to fatigue in these
Search Results
Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas
George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III
symptoms; comorbidities; family history; and exposure to antineoplastic drugs and radiation. Common complaints are syncope, exercise dyspnea, headache, vertigo, chest pain, fatigue (disruptive to work and daily activities), and abnormal menstruation in
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Featured Updates to the NCCN Guidelines
John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh
, but especially if the cough is dry or is coupled with shortness of breath, it could indicate pneumonitis . Headaches can be indicative of brain metastases, but when presenting with fatigue , visual symptoms , nausea , and other symptoms, may be
Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria
Fatigue Inventory has helped evaluate the fitness of older patients for cancer surgery. 13 – 15 Clinical trials are ongoing to establish more simplified, time-efficient, and validated instruments to quantify fitness for various forms of therapy. Recent
Atish D. Choudhury and Philip W. Kantoff
incidences of all grades of fatigue (34% vs. 29%), diarrhea (21% vs. 18%), hot flashes (20% vs. 10%), musculoskeletal pain (14% vs. 10%), and headache (12% vs. 6%) were seen with enzalutamide (statistical significance for these events was not reported). Also
Jerome Kim and Arti Hurria
have linked depression to hospitalizations, 6 chemotherapy toxicity, and decreased survival in older adults with cancer. 9 Studies have noted loss of independence and fatigue as leading causes of patient distress, which leads to a reduced ability to
Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar
fatigue, and overall greater burden than patients with other cancer types. 16 , 17 Despite the distinct burdens of patients with PDAC, it is still poorly understood which domains of the PROMIS item banks are prioritized by these patients. After a 2016
Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary
carcinoma ( Figure 1D–F ). However, among the 4 tubular-type PDACs, 1 showed prominent extracellular mucin. Clinical presentation, treatment, and follow-up information was available for 4 of 5 patients. Case 1 A 35-year-old man presented with fatigue
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
) The most common grade 1/2 toxicities with FOLFOX were fatigue (58%), nausea (32%), and neutropenia (25%). The most common grade 3 toxicities were diarrhea (4%), fatigue (1%), nausea (1%), and neutropenia (1%). These were managed with dose reductions
Crystal S. Denlinger, Robert W. Carlson, Madhuri Are, K. Scott Baker, Elizabeth Davis, Stephen B. Edge, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Elizabeth Kvale, Terry S. Langbaum, Jennifer A. Ligibel, Mary S. McCabe, Kevin T. McVary, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Tracey O’Connor, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian, and Deborah Freedman-Cass
Guidelines for Survivorship, the panel focused on 8 common issues of survivors: 1) anxiety and depression, 2) cognitive decline, 3) pain, 4) female and male sexual dysfunction, 5) immunizations and prevention of infections, 6) fatigue, 7) sleep disorders, and
